UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG Patent applications |
Patent application number | Title | Published |
20160101176 | POLYMERIC HYDROGEL PHARMACEUTICAL COMPOSITIONS WITH ON-DEMAND RELEASE OF A DRUG IN RESPONSE TO A ELECTRICAL STIMULUS - A polymeric hydrogel pharmaceutical dosage form for drug delivery to a target site of a human or animal. The dosage form includes polyethylene-imine (PEI) and 1-vinylimidazole (1VA), the dosage form being electro-responsive in use. Also, methods of manufacturing the dosage form and methods of treating chronic pain utilizing the dosage form. | 04-14-2016 |
20150274765 | RAPIDLY DISSOLVING PHARMACEUTICAL COMPOSITION - The present invention relates to a pharmaceutical dosage form which may comprise carbamoyl glycinated chitosan, and particularly it relates to a pharmaceutical dosage form comprising the novel polymer in a lyophilized polymeric wafer form which shows rapid disintegration and dissolution characteristics in use. | 10-01-2015 |
20150209275 | Fast Dissolving Ocular Insert - This invention relates to a pharmaceutical dosage form, particularly to a topical ocular pharmaceutical dosage form comprising a polymeric matrix of polyethylene oxide block copolymer, preferably polyoxyethylene-polyoxypropylene block copolymer and hydroxpropyl cellulose, and a pharmaceutically active ingredient incorporated within the matrix. The invention extends to a method of manufacturing the pharmaceutical dosage form. | 07-30-2015 |
20140378299 | THERMALLY STABLE NANO-CATALYST - This invention relates to a titanium dioxide catalyst particle, the catalyst particle comprising ruffle nanorods having metal nanoparticles deposited at or near the free ends of the nanorods, which is suitable to catalyse reactions after exposure to temperatures above 550 deg C. The invention also provides for the use of a catalyst particle in catalysing reactions and a method of catalysing reactions, the catalyst particle being suitable to catalyse reactions after exposure to temperatures above 550 deg C. | 12-25-2014 |
20140350080 | INHIBITION OF VIRAL GENE EXPRESSION - This invention relates to modified short interfering RNA (siRNA) nucleic acid molecules, particularly siRNA's which have been modified by the addition of a 2-0-guanidinopropyl (GP) modified nucleoside. In particular the invention relates to modified siRNAs which are capable of silencing target sequences, methods of treating and preventing infection by using the siRNAs, medicaments containing the siRNAs and use of the siRNAs. | 11-27-2014 |
20140220041 | COMPOUNDS FOR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE - The invention relates to a method of modulating concentration of Alzheimer's Disease (AD) relevant proteins amyloid precursor protein (APP), beta (β) and gamma (γ) secretases and amyloid beta peptide (Aβ), and also relates to a method of reducing Aβ shedding. Furthermore, this invention extends to a compound for use in the treatment of AD, and also to a method of treating AD. | 08-07-2014 |
20140148495 | MONOLITHIC DRUG DELIVERY SYSTEM - An improved monolithic drug delivery dosage form releases a pharmaceutically active agent at a predetermined rate. The dosage form comprises a salted-out or crosslinked polymer and a pharmaceutically active agent. The salted-out or crosslinked polymer functions to polymerically entangle the pharmaceutically active agent but, progressively relaxes on contact with an aqueous medium in use to release the pharmaceutically active agent at a predetermined rate. | 05-29-2014 |
20140005269 | POLYMERIC MATRIX OF POLYMER-LIPID NANOPARTICLES AS A PHARMACEUTICAL DOSAGE FORM | 01-02-2014 |
20140005199 | IMPLANT FOR THE CONTROLLED RELEASE OF PHARMACEUTICALLY ACTIVE AGENTS | 01-02-2014 |
20140004185 | PHARMACEUTICAL COMPOSITION | 01-02-2014 |
20130337022 | PHARMACEUTICAL DOSAGE FORM - A pH responsive and mucoadhesive pharmaceutical dosage form for the release of a pharmaceutically active agent is described. The dosage form includes a mucoadhesive layer for site-specific mucoadhesion, a water-insoluble outer layer, and an intermediate layer including one or more pharmaceutically active agents for site-specific delivery. The different membranous layers perform different functions in order to create a drug delivery system which is able to deliver a drug to a specific site, for a particular period of time and with a specific drug release pattern. The dosage form can have two or more intermediate layers, each layer comprising an active agent. The mucoadhesive layer can also include an active agents. The dosage form is preferably an oral or buccal delivery form for release of the active agent into the gastro intestinal tract. The intermediate layer can be an electrospun fibrous membrane layer containing the active agent. | 12-19-2013 |
20130252916 | ORAMUCOSAL PHARMACEUTICAL DOSAGE FORM - This invention relates to an oramucosal pharmaceutical dosage form in the form of a wafer. The wafer comprises a porous, hydroscopic, muco-adhesive polymeric matrix with at least one desired pharmaceutically active compound added thereto. The polymer is selected from a number of polymers having different dissolution rates and, in use when taken orally, the matrix adheres to an oramucosal surface to dissolve over a predetermined period of time to release the pharmaceutically active compound. The invention also extends to a method of manufacturing an oramucosal pharmaceutical dosage form in the form of a wafer which involves freeze drying or lyophilisation. | 09-26-2013 |
20130052645 | METHOD FOR IDENTIFYING BACTERIA IN A SAMPLE - This invention describes a method for identifying bacteria. In particular, this invention relates to a method for identifying and quantifying mycobacteria from a sputum sample taken from a subject using flow cytometry. Further described is the use of flow cytometry to identify and quantify | 02-28-2013 |
20120241675 | Carbon Absorbing System Used in the Production of Synthesis Gas - A system for the production of synthesis gas and, for the production thereof, where the system is preferably a net carbon dioxide absorber. The invention covers both the methodology for the development of the process and the system for the implementation of the process, inclusive of the required utility systems. | 09-27-2012 |
20120106699 | METHOD AND APPARATUS FOR RADIATION IMAGING - This invention relates to a method and an apparatus, primarily a radiation imaging apparatus and an array of coded aperture masks, for use in diagnostic nuclear medicine. The coded aperture masks are fitted with radiation attenuation tubes, each of which extends from each side of the mask in the direction of the mask apertures. The tubes are made from lead and have parallel sides. The masks are configured for gamma ray usage and are made from tungsten having a thickness of between 1 and 2 mm. | 05-03-2012 |
20120088266 | BIOREACTOR PROCESS FOR PRODUCTION OF HYDROGEN FROM BIOMASS - This invention relates to bioreactor processes, particularly bioreactor processes for the production of hydrogen gas from biomass, more particularly to bioreactor processes for the production of hydrogen gas employing a mixed anaerobic thermophilic bacterial consortium during the anaerobic fermentation of biomass. | 04-12-2012 |
20120064142 | POLYMERIC PHARMACEUTICAL DOSAGE FORM IN SUSTAINED RELEASE - This invention relates to a polymeric pharmaceutical dosage form for the delivery, in use, of at least one pharmaceutical composition in a rate-modulated and site-specific manner. The dosage form comprises a biodegradable, polymeric, scaffold incorporating loaded with at least one active pharmaceutical ingredient (API). The polymer or polymers making up the scaffold degrade in a human or animal body in response to or in the absence of specific biological stimuli and, on degradation, release the API or APIs in an area where said stimuli are encountered. Preferably the polymeric scaffold is formed from poly (D1L-lactide) (PLA) and polymethacrylate (Eudragit S100/ES100) polymers. | 03-15-2012 |
20110307074 | BIOMATERIALS FOR USE IN METHODS OF BONE REPLACEMENT THERAPY - This invention relates to biomaterials, said biomaterials for use in methods to control and/or induce bone growth. Particularly, the invention relates to macroporous calcium phosphate biomaterials pre-loaded with certain amounts of osteoclastic activity inhibitors for use in methods to control and/or induce bone growth in primates. | 12-15-2011 |
20110190881 | Artificial Larynx - This invention relates to a means for compensating for a whole or partial loss of speech. The means has a sensor unit in the form of a Logometrix pseudo palate and a palatometer which sense the position of a user's tongue while endeavouring to articulate words or sounds. The sensor unit is connected to a comparator which makes use of suitable artificial intelligence algorithms (such as Multi-Layer Perceptron Neural Networks and Hidden Markov Models) together with a library of stored words and sounds as well as tongue positions and signals related to jaw and lip movement as well as inhalation and exhalation to match words or sounds and transmit the matched words or sounds to a loudspeaker. Preferably the output of the loudspeaker will simulate the natural voice of the user. | 08-04-2011 |
20110190616 | CODED APERTURE MASKS FOR RADIATION-BASED MEDICAL IMAGING - This invention relates to a coded aperture mask for use in diagnostic nuclear medicine imaging. The coded aperture mask consists of a sheet of radiation opaque mask material having a series of apertures extending therethrough. The thickness of mask material has an attenuation percentage of less than 75% and, in a preferred embodiment, about equal to 29%. The coded aperture mask also, in a preferred embodiment, has a lead attenuation tube and has a projection of the smallest hole occupying the same area as a single pixel of a detector. The invention extends to a diagnostic nuclear medicine imaging system which uses a 16 bit gamma camera as a radiation detector. | 08-04-2011 |
20100323007 | A POLYAMIDE RATE-MODULATED MONOLITHIC DRUG DELIVERY SYSTEM - This invention relates to a polyamide rate-modulated monolithic drug delivery system comprising at least one active compound and a biodegradable and biocompatible polyamide polymer. The polymer is selected for delivering, in use, the active compound, within a predetermined time frame depending on the biodegradable properties of the polymer, to a target organism or organisms. In one embodiment of the invention the polymer is modified by salting-out or crosslinking the polymeric material to achieve the desired biodegradability characteristics and, consequently, to control the release of the active compound. | 12-23-2010 |
20100304420 | BIOREACTOR FOR MESOPHILIC AND/OR THERMOPHILIC FERMENTATION - This invention relates to a bioreactor for producing high rates of hydrogen from plant biomass. It also relates to the rapid screening, selection and isolation of biofilm forming mesophilic and/or thermophilic bacteria or bacteria consortia that generate high levels of hydrogen from plant biomass or from soluble hydrolysates derived from the hydrolysis of cellulosic materials including hemicellulose. The reactor comprises a primary reactor vessel having a bed of hydrogen producing bacteria towards its base located within a secondary reactor vessel which functions as a hydrogen gas collector and as a clarifier and separator. The plant biomass may be one or a mixture of insoluble cellulosic material and a hydrolysate derived from hydrolysis of cellulosic material. In one embodiment the bed of the primary reactor vessel is fluidised by recycling hydrogen gas saturated plant biomass effluent from the secondary reactor vessel to the primary reactor vessel. | 12-02-2010 |
20100068169 | MONOLITHIC DRUG DELIVERY SYSTEM - This invention relates to an improved monolithic drug delivery dosage form which releases a pharmaceutically active agent at a predetermined rate. The dosage form comprises a salted-out or crosslinked polymer and a pharmaceutically active agent. The salted-out or crosslinked polymer functions to polymerically entangle the pharmaceutically active agent but, progressively relax on contact with an aqueous medium in use to release the pharmaceutically active agent at a predetermined rate. | 03-18-2010 |
20090203733 | PHARMACEUTICAL COMPOSITION - This invention relates to a pharmaceutical composition for mammals and, more particularly, to a pharmaceutical composition which enhances the action of an anaesthetic used in both human and veterinary applications, which, at least partly, reduces the risk of respiratory depression and enhances pulmonary perfusion. The pharmaceutical composition is characterised in that it contains a serotonergic ligand or any pharmacologically acceptable salt or ester thereof which acts on at least one member of the 5-HT family of serotonergic receptors, preferably on one or more of the 5-HTiA, 5-HT4 and 5-HT7 serotonergic receptors. In an example the ligand is the 8-OH-DPAT ligand. The composition can be used in conjunction with or include an anaesthetic, preferably an opioid anaesthetic, to induce a state of anaesthesia in mammals and it can be used to immobilise wile or non-domestic mammals. | 08-13-2009 |
20080296504 | Method and Apparatus for Radiation Imaging - This invention relates to a method and an apparatus, primarily a radiation imaging apparatus and an array of coded aperture masks, for use in diagnostic nuclear medicine. The coded aperture masks are fitted with radiation attenuation tubes, each of which extends from each side of the mask in the direction of the mask apertures. The tubes are made from lead and have parallel sides. The masks are configured for gamma ray usage and are made from tungsten having a thickness of between 1 and 2 mm. | 12-04-2008 |
20080247939 | Process for Producing Carbon Nanotubes - The invention provides a process for producing carbon nanotubes which includes supplying a continuous fluidized feed of a catalyst and at least one hydrocarbon to a reactor operating under conditions suitable to produce carbon nanotubes. The fluid is made to flow though the reactor with a swirling motion which ensures that the internal surfaces of the reactor are cleaned of deposits. | 10-09-2008 |